Kiora Pharmaceuticals (KPRX) Other Non-Current Assets (2015 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Other Non-Current Assets came in at $4687.0 in Q1 2026, down 92.71% YoY from $64323.0 in Q1 2025, and up 2.65% on a QoQ basis from $4566.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Other Non-Current Assets (2015 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 12 years of Other Non-Current Assets data on file, last reported at $4687.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 92.71% year-over-year to $4687.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4687.0 (down 92.71% YoY) and the FY2025 annual result came in at $4566.0, down 81.67% from the prior year.
- Other Non-Current Assets rose to $4687.0 in Q1 2026, from $4566.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $64323.0 in Q1 2025 to a low of $4031.0 in Q3 2023.
- A 5-year average of $25791.3 and a median of $24913.0 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets jumped 1475.0% — and 2026, when it sank 92.71%.
- Tracing KPRX's Other Non-Current Assets over 5 years: stood at $49300.0 in 2022, then slumped by 91.34% to $4267.0 in 2023, then jumped by 483.85% to $24913.0 in 2024, then plunged by 81.67% to $4566.0 in 2025, then advanced by 2.65% to $4687.0 in 2026.
- The last three Other Non-Current Assets figures came in at $4687.0 (Q1 2026), $4566.0 (Q4 2025), and $58135.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | 85,379.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85,379.00 |
| Mar 31, 2026 | 4,687.00 |
| Dec 31, 2025 | 4,566.00 |
| Sep 30, 2025 | 58,135.00 |
| Jun 30, 2025 | 4,461.00 |
| Mar 31, 2025 | 64,323.00 |
| Dec 31, 2024 | 24,913.00 |
| Sep 30, 2024 | 4,520.00 |
| Jun 30, 2024 | 32,122.00 |
| Mar 31, 2024 | 4,084.00 |
| Dec 31, 2023 | 4,267.00 |
| Sep 30, 2023 | 4,031.00 |
| Jun 30, 2023 | 4,150.00 |
| Mar 31, 2023 | 32,669.00 |
| Dec 31, 2022 | 49,300.00 |
| Sep 30, 2022 | 49,037.00 |
| Jun 30, 2022 | 39,367.00 |
| Mar 31, 2022 | 53,820.00 |
| Dec 31, 2021 | 45,000.00 |
| Sep 30, 2021 | 45,000.00 |